Zanubrutinib Approved in Waldenstrom Macroglobulinemia and MZL

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：649 / 649
页数：1
相关论文
共 50 条
  • [21] ASPEN: Results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrom Macroglobulinemia (WM)
    Buske, C.
    Dimopoulos, M.
    Opat, S.
    D'Sa, S.
    Jurczak, W.
    Lee, H-P
    Cull, G.
    Owen, R. G.
    Marlton, P.
    Wahlin, B. E.
    Garcia, Sanz R.
    McCarthy, H.
    Mulligan, S.
    Tedeschi, A.
    Castillo, J.
    Czyz, J.
    Fernandez De Larrea, C.
    Belada, D.
    Libby, E.
    Matous, J.
    Motta, M.
    Siddiqi, T.
    Tani, M.
    Trneny, M.
    Minnema, M.
    Leblond, V
    Chan, W. Y.
    Schneider, J.
    Cohen, A.
    Huang, J.
    Tam, C. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 107 - 108
  • [22] WALDENSTROM MACROGLOBULINEMIA
    MARIA, JSD
    JIMENEZ, CB
    IZAGUERRI, RE
    RODRIGUEZ, ED
    CALOCA, JPC
    SABATE, JMB
    MIRANDA, MP
    REVISTA CLINICA ESPANOLA, 1984, 172 (01): : 1 - 3
  • [23] Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenstrom Macroglobulinemia: A Prospective, Phase II Study
    Yu, Ying
    Yi, ShuHua
    Wenjie, Xiong
    Wang, Tingyu
    Yan, Yuting
    Liu, Wei
    Sui, Weiwei
    An, Gang
    Xu, Yan
    Liu, Huimin
    Huang, Wenyang
    Zou, Dehui
    Qiu, Lugui
    BLOOD, 2022, 140 : 3587 - 3588
  • [24] ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrom macroglobulinemia (WM).
    Tam, Constantine Si Lun
    Opat, Stephen
    D'Sa, Shirley
    Jurczak, Wojciech
    Lee, Hui-Peng
    Cull, Gavin
    Owen, Roger G.
    Marlton, Paula
    Wahlin, Bjorn E.
    Tedeschi, Alessandra
    Castillo, Jorge J.
    Siddiqi, Tanya
    Buske, Christian
    Leblond, Veronique
    Chan, Wai Y.
    Schneider, Jingjing
    Ro, Sunhee K.
    Cohen, Aileen
    Huang, Jane
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia
    Tam, Constantine S.
    LeBlond, Veronique
    Novotny, William
    Owen, Roger G.
    Tedeschi, Alessandra
    Atwal, Siminder
    Cohen, Aileen
    Huang, Jane
    Buske, Christian
    FUTURE ONCOLOGY, 2018, 14 (22) : 2229 - 2237
  • [26] ASPEN: RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB FOR PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA (WM)
    Tedeschi, A.
    Dimopoulos, M.
    Opat, S.
    D'Sa, S.
    Jurczak, W.
    Lee, H.
    Cull, G.
    Owen, R.
    Marlton, P.
    Wahlin, B.
    Garcia Sanz, R.
    McCarthy, H.
    Mulligan, S.
    Castillo, J.
    Czyz, J.
    Fernandez De Larrea, C.
    Belada, D.
    Libby, E.
    Matous, J.
    Motta, M.
    Siddiqi, T.
    Tani, M.
    Trneny, M.
    Minnema, M.
    Buske, C.
    Leblond, V.
    Chan, W.
    Schneider, J.
    Cohen, A.
    Huang, J.
    Tam, C.
    HAEMATOLOGICA, 2021, 106 (10) : 9 - 10
  • [27] ASPEN: RESULTS OF A RANDOMIZED PHASE III TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
    Dimopoulos, M.
    Opat, S.
    D'Sa, S.
    Jurczak, W.
    Lee, H.
    Cull, G.
    Owen, R. G.
    Marlton, P.
    Wahlin, B. E.
    Garcia, Sanz R.
    McCarthy, H.
    Mulligan, S.
    Tedeschi, A.
    Castillo, J.
    Czyz, J.
    Fernandez, De Larrea C.
    Belada, D.
    Motta, M.
    Tani, M.
    Trneny, M.
    Minnema, M.
    Buske, C.
    Leblond, V
    Cohen, A.
    Tam, C. S.
    HAEMATOLOGICA, 2021, 106 (10) : 310 - 310
  • [28] "Real-Life" Data of Zanubrutinib in Patients with Waldenstrom Macroglobulinemia - a Multi-Center Retrospective Study
    Itchaki, Gilad
    Benjamini, Ohad
    Levi, Mor
    Nemets, Anatoly
    Yeganeh, Shay
    Assaly, Mahdi
    Gourevitch, Anna
    Saban, Revital
    Gatt, Moshe E.
    Raanani, Pia
    Vaxman, Iuliana
    BLOOD, 2022, 140 : 11981 - 11982
  • [29] Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrom macroglobulinemia in the United States.
    Castillo, Jorge J.
    Yang, Keri
    Liu, Rongzhe
    Wang, Yu
    Cohen, Aileen
    Zimmerman, Todd M.
    Zhao, Qian
    van de Wetering, Gijs
    Gao, Xin
    Tang, Boxiong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] IGG WALDENSTROM MACROGLOBULINEMIA
    VELASCO, FP
    MEDICINA CLINICA, 1992, 99 (20): : 798 - 798
12345